Filtros : "Financiamento MMV" "Financiamento NIH" Removidos: "Geografia Humana" "MOREIRA, ANA CAROLINA TAKAKURA" "aku" "vtu" Limpar

Filtros



Limitar por data


  • Fonte: Nature Communications. Unidade: IFSC

    Assuntos: PLASMODIUM FALCIPARUM, PLANEJAMENTO DE FÁRMACOS, ANTIPARASITÁRIOS, MALÁRIA

    Versão PublicadaAcesso à fonteDOIComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      VRIES, Laura E. e AGUIAR, Anna Caroline Campos e GUIDO, Rafael Victorio Carvalho. Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183. Nature Communications, v. 13, p. 2158-1-2158-16, 2022Tradução . . Disponível em: https://doi.org/10.1038/s41467-022-29688-5. Acesso em: 28 ago. 2024.
    • APA

      Vries, L. E., Aguiar, A. C. C., & Guido, R. V. C. (2022). Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183. Nature Communications, 13, 2158-1-2158-16. doi:10.1038/s41467-022-29688-5
    • NLM

      Vries LE, Aguiar ACC, Guido RVC. Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183 [Internet]. Nature Communications. 2022 ; 13 2158-1-2158-16.[citado 2024 ago. 28 ] Available from: https://doi.org/10.1038/s41467-022-29688-5
    • Vancouver

      Vries LE, Aguiar ACC, Guido RVC. Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183 [Internet]. Nature Communications. 2022 ; 13 2158-1-2158-16.[citado 2024 ago. 28 ] Available from: https://doi.org/10.1038/s41467-022-29688-5
  • Fonte: Journal of Medicinal Chemistry. Unidade: IFSC

    Assuntos: ANTIMALÁRICOS, PLASMODIUM FALCIPARUM, PLANEJAMENTO DE FÁRMACOS, ANTIPARASITÁRIOS, MALÁRIA, BIOQUÍMICA, QUÍMICA MÉDICA

    Versão PublicadaAcesso à fonteDOIComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      TAFT, Benjamin R. e AGUIAR, Anna Caroline Campos. Discovery and preclinical pharmacology of INE963, a potent and fast-acting blood-stage antimalarial with a high barrier to resistance and potential for single-dose cures in uncomplicated malaria. Journal of Medicinal Chemistry, v. 65, n. 5, p. 3798-3813, 2022Tradução . . Disponível em: https://doi.org/10.1021/acs.jmedchem.1c01995. Acesso em: 28 ago. 2024.
    • APA

      Taft, B. R., & Aguiar, A. C. C. (2022). Discovery and preclinical pharmacology of INE963, a potent and fast-acting blood-stage antimalarial with a high barrier to resistance and potential for single-dose cures in uncomplicated malaria. Journal of Medicinal Chemistry, 65( 5), 3798-3813. doi:10.1021/acs.jmedchem.1c01995
    • NLM

      Taft BR, Aguiar ACC. Discovery and preclinical pharmacology of INE963, a potent and fast-acting blood-stage antimalarial with a high barrier to resistance and potential for single-dose cures in uncomplicated malaria [Internet]. Journal of Medicinal Chemistry. 2022 ; 65( 5): 3798-3813.[citado 2024 ago. 28 ] Available from: https://doi.org/10.1021/acs.jmedchem.1c01995
    • Vancouver

      Taft BR, Aguiar ACC. Discovery and preclinical pharmacology of INE963, a potent and fast-acting blood-stage antimalarial with a high barrier to resistance and potential for single-dose cures in uncomplicated malaria [Internet]. Journal of Medicinal Chemistry. 2022 ; 65( 5): 3798-3813.[citado 2024 ago. 28 ] Available from: https://doi.org/10.1021/acs.jmedchem.1c01995
  • Fonte: Proceedings of the National Academy of Sciences of the United States of America - PNAS. Unidade: IFSC

    Assuntos: PLASMODIUM FALCIPARUM, PLANEJAMENTO DE FÁRMACOS, MALÁRIA, QUÍMICA MÉDICA

    PrivadoAcesso à fonteDOIComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      XIE, Stanley C. e AGUIAR, Anna Caroline Campos e GUIDO, Rafael Victorio Carvalho. Design of proteasome inhibitors with oral efficacy in vivo against Plasmodium falciparum and selectivity over the human proteasome. Proceedings of the National Academy of Sciences of the United States of America - PNAS, v. 118, n. 39, p. e2107213118-1-e2107213118-9, 2021Tradução . . Disponível em: https://doi.org/10.1073/pnas.2107213118. Acesso em: 28 ago. 2024.
    • APA

      Xie, S. C., Aguiar, A. C. C., & Guido, R. V. C. (2021). Design of proteasome inhibitors with oral efficacy in vivo against Plasmodium falciparum and selectivity over the human proteasome. Proceedings of the National Academy of Sciences of the United States of America - PNAS, 118( 39), e2107213118-1-e2107213118-9. doi:10.1073/pnas.2107213118
    • NLM

      Xie SC, Aguiar ACC, Guido RVC. Design of proteasome inhibitors with oral efficacy in vivo against Plasmodium falciparum and selectivity over the human proteasome [Internet]. Proceedings of the National Academy of Sciences of the United States of America - PNAS. 2021 ; 118( 39): e2107213118-1-e2107213118-9.[citado 2024 ago. 28 ] Available from: https://doi.org/10.1073/pnas.2107213118
    • Vancouver

      Xie SC, Aguiar ACC, Guido RVC. Design of proteasome inhibitors with oral efficacy in vivo against Plasmodium falciparum and selectivity over the human proteasome [Internet]. Proceedings of the National Academy of Sciences of the United States of America - PNAS. 2021 ; 118( 39): e2107213118-1-e2107213118-9.[citado 2024 ago. 28 ] Available from: https://doi.org/10.1073/pnas.2107213118

Biblioteca Digital de Produção Intelectual da Universidade de São Paulo     2012 - 2024